 Photo courtesy of Genzyme |
Amgen continues to rule the Top 10 Biopharma rankings, but 2005 saw a couple of players make great strides. Genentech and Gilead continued to post huge gains (+46% each) on the strength of their oncology and HIV drugs, respectively.
Chiron also eked its way back into the billion-dollar ranks after its vaccine-manufacturing disaster in 2004, but it wasn’t enough to help the company stay independent; the company was bought by Novartis and will disappear from this chart next year.
—Gil Y. Roth
Editor
ContributorsEditor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
Top 10 Biopharmaceutical Companies |
||
based on 2005 biopharma revenues |
||
| 1 | Amgen | $12,022 |
| 2 | Genentech | $5,488 |
| 3 | Serono | $2,339 |
| 4 | Biogen Idec | $2,326 |
| 5 | Gilead Sciences |
$1,809 |
| 6 | Genzyme Corp. |
$1,773 |
| 7 | MedImmune | $1,221 |
| 8 | Chiron Corp. | $1,138 |
| 9 | Millennium Pharmaceuticals |
$316 |
| 10 | ImClone | $221 |
2005 R&D Expenditures |
||
| 1 | Amgen | $2,314 |
| 2 | Genentech | $1,262 |
| 3 | Biogen Idec | $747 |
| 4 | Serono | $594 |
| 5 | Genzyme Corp. |
$503 |
| 6 | Chiron Corp. | $434 |
| 7 | MedImmune | $385 |
| 8 | Millennium Pharmaceuticals |
$342 |
| 9 | Gilead Sciences |
$278 |
| 10 | ImClone | $99 |
|
|
||
